Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Quetiapine-XR Clear all
Completed Phase 3 Interventional

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04513912
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Matching placebo to Seltorexant, Quetiapine XR, Matching placebo to Quetiapine XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
75
States / cities
Birmingham, Alabama • Tucson, Arizona • Culver City, California + 62 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency

NCT01165541
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Mirtazapine, Quetiapine fumarate extended release (Quetiapine XR)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Bedford, New Hampshire • Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 8, 2018 · Synced Sep 4, 2026, 1:46 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

NCT04373317
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
24
States / cities
Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence

NCT00434876
View directory record Official record
Conditions
Alcoholism, Sleep Initiation and Maintenance Disorders
Interventions
Quetiapine XR, Placebo.
Drug
Lead sponsor
Subhajit Chakravorty
Federal
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

NCT01727726
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
Brexpiprazole, Seroquel XR, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

Quetiapine for the Reduction of Cocaine Use

NCT00631748
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
Interventions
quetiapine fumarate, Matched Placebo, Cognitive-behavioral Therapy
Drug · Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients

NCT00951483
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Quetiapine-XR
Drug
Lead sponsor
Loyola University
Other
Eligibility
20 Years to 65 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

NCT00893841
View directory record Official record
Conditions
Bipolar Depression
Interventions
quetiapine (Seroquel) XR, placebo, pramipexole dihydrochloride
Drug
Lead sponsor
Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
San Diego, California • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)

NCT00880919
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
quetiapine extended-release, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Iowa City, Iowa • Belmont, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 4, 2026, 1:46 PM EDT
Terminated Phase 4 Interventional Results available

Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines

NCT01244711
View directory record Official record
Conditions
Major Depression, Generalized Anxiety Disorder
Interventions
quetiapine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat

NCT01971203
View directory record Official record
Conditions
Major Depressive Disorder, Generalized Anxiety Disorder
Interventions
seroquel xr, CBT
Drug · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole in Patients With Acute Schizophrenia

NCT01810380
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Brexpiprazole, Quetiapine extended release
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

NCT00790192
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Quetiapine XR, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Quetiapine in Melancholic Depression

NCT01200901
View directory record Official record
Conditions
Depression, Healthy
Interventions
Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD

NCT02720198
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran, Quetiapine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Alpharetta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency

NCT00498628
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse
Interventions
Quetiapine fumarate, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Boston, Massachusetts • Lebanon, New Hampshire • Philadelphia, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation Comparison

NCT00702676
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Results available

Brain Imaging of Quetiapine Response in Anxious Depression

NCT00982345
View directory record Official record
Conditions
Major Depression
Interventions
quetiapine (Seroquel XR)
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

NCT04115319
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP363856, quetiapine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Cerritos, California • Oakland, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 4, 2026, 1:46 PM EDT
Terminated Phase 3 Interventional Results available

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder

NCT00868374
View directory record Official record
Conditions
Major Depressive Disorder, Generalized Anxiety Disorder
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
Keming Gao
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 4, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)

NCT00671853
View directory record Official record
Conditions
Bipolar Disorder, Anxiety, Anxiety Disorders, Substance Use Disorders
Interventions
Quetiapine XR, Placebo for quetiapine XR
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 4, 2026, 1:46 PM EDT
Terminated Phase 4 Interventional Results available

Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder

NCT00746421
View directory record Official record
Conditions
Bipolar Disorder, Cognitive Impairment
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 4, 2026, 1:46 PM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 4, 2026, 1:46 PM EDT
Terminated Phase 4 Interventional Results available

Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms

NCT00955474
View directory record Official record
Conditions
Major Depressive Disorder With Psychotic Features
Interventions
Quetiapine, escitalopram, Sertraline, Citalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 4, 2026, 1:46 PM EDT